Genmab To Acquire Merus In $8 Bln Cash Deal

Genmab A/S has agreed to acquire Merus NV for approximately $8.0 billion in an all-cash transaction, paying $97.00 per share, representing a 41% premium. This strategic acquisition is primarily driven by Merus' late-stage asset, petosemtamab, a potentially transformational head and neck cancer therapy with Breakthrough Therapy Designations, which Genmab projects will generate over $1 billion in annual sales by 2029 and multi-billion-dollar revenue potential thereafter. The deal, funded by cash and $5.5 billion in debt, is expected to close in early Q1 2026 and positions Genmab for multiple new drug launches by 2027, though it will not impact its 2025 financial guidance.

Analysis

Genmab A/S is undertaking a significant strategic expansion with its definitive agreement to acquire Merus NV in an all-cash transaction valued at approximately $8.0 billion. The offer of $97.00 per share represents a substantial 41% premium, underscoring Genmab's high conviction in the target's pipeline. The central asset in this acquisition is petosemtamab, a late-stage therapy for head and neck cancer with two Breakthrough Therapy Designations, which Genmab positions as a transformational product. Genmab has issued aggressive financial projections for the asset, anticipating it will be accretive to EBITDA post-approval and generate annual sales exceeding $1 billion by 2029, with multi-billion-dollar revenue potential thereafter. The transaction will be financed through a combination of existing cash and approximately $5.5 billion in non-convertible debt, backed by a commitment from Morgan Stanley, which mitigates financing risk. Despite the scale of the deal, Genmab has reaffirmed its full-year 2025 financial guidance, signaling confidence in its existing operations, while the acquisition is set to bolster its late-stage pipeline to four proprietary programs expected to launch by 2027. The deal is anticipated to close in the first quarter of 2026, subject to a tender offer.

Key Decisions for Investors

• For Merus (MRUS) shareholders, the $97.00 all-cash offer represents a significant premium and a clear monetization event, with a high probability of completion given the unanimous board approvals and committed financing.
• For Genmab (GMAB) investors, this is a transformative but leverage-increasing acquisition; future returns will be highly dependent on the successful clinical development and commercial execution of petosemtamab to justify the purchase price and service the new $5.5 billion in debt.
• Investors should closely monitor Genmab's forthcoming 2026 financial outlook, which will be the first to incorporate the acquisition's impact, and track all regulatory milestones for petosemtamab as they are now the primary value drivers for the combined entity.